Fennec Pharmaceuticals Inc. (TSX:FRX)
Canada · Delayed Price · Currency is CAD 11.64
-0.34 (-2.84%)
Jul 18, 2025, 1:11 PM EDT
Fennec Pharmaceuticals Company Description
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.
It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.
Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Inc.
| Country | Canada |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Jeffrey Hackman |
Contact Details
Address: 68 TW Alexander Drive Research Triangle Park, British Columbia 27709 United States | |
| Phone | 919 636 4530 |
| Website | fennecpharma.com |
Stock Details
| Ticker Symbol | FRX |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CA31447P1009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey S. Hackman | Chief Executive Officer and Director |
| Robert C. Andrade | Chief Financial Officer |
| Dr. Pierre S. Sayad M.S., Ph.D. | Chief Medical Officer |
| Terry Evans | Chief Commercial Officer |
| Christiana Cioffi M.B.A. | Chief Strategy Officer |
| Mark Gowland | Controller |
| Lei Fang | President of Pharstat Inc |